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Statin therapy and recurrent 
venous thromboembolism in the 
elderly: a prospective cohort study
Regula Monika Kronenberg1,6, Shanthi Beglinger  1,2, Odile Stalder3, Marie Méan4, 
Andreas Limacher3, Jürg Hans Beer5, Drahomir Aujesky1, Nicolas Rodondi1,2 & Martin feller1,2
previous studies reported lower rates of recurrent venous thromboembolism (rVte) among statin 
users, but this association could be influenced by concurrent anticoagulation and confounding by 
statin indication. This study aimed to confirm the beneficial association between statins and rVTE, 
stratified according to periods with and without anticoagulation, and additionally employ propensity 
score weighted approach to reduce risk of confounding by indication. the setting was a prospective 
multicentre cohort study and the outcome was time to first rVTE in statin vs. non-statin users. 980 
participants with acute VTE were enrolled (mean age 75.0 years, 47% women), with median follow-up 
of 2.5 years. Of 241 (24.3%) statin users, 21 (8.7%) suffered rVTE vs. 99 (13.4%) among 739 non-
users. The overall adjusted sub-hazard ratio (aSHR) for rVTE comparing statin users to non-users 
was 0.72 (95%CI 0.44 to 1.19, p = 0.20). This association was only apparent during periods without 
anticoagulation (aSHR 0.50, 95%CI 0.27 to 0.92, p = 0.03; vs. with anticoagulation: aSHR 1.34, 95%CI 
0.54 to 3.35, p = 0.53). Using propensity scores, the rVTE risk during periods without anticoagulation 
fell further (aSHR 0.20, 95%CI 0.08 to 0.49, p < 0.001). In conclusion, statin use is associated with a 
more pronounced risk reduction for rVTE than previously estimated, but only during periods without 
anticoagulation.
A recent systematic review and meta-analysis of randomised clinical trials (RCT) and observational studies 
demonstrated a 15–25% risk reduction in a first episode of venous thromboembolism (VTE) with statin use1. The 
underlying mechanism of action for this benefit could lie in a reduction of markers of inflammation2, resulting 
in a decreased coagulant state and ultimately a reduced risk for VTE3,4. For persons who have already suffered a 
VTE, an RCT with statins is lacking. According to a meta-analysis of eight observational studies, the risk of recur-
rent VTE (rVTE) was 27% lower under statin therapy, and this association was homogenous across the included 
studies (I2 = 0%), but results were not stratified according to whether or not patients took anticoagulants5.
Statin users are more likely to be older (>60 years) and suffer from cardiovascular comorbidities which 
predispose for VTE, compared to non-users6–8. In this instance, a traditional multivariable statistical analysis 
approach may fall short of balancing comorbidities between statin users and non-users, and the results could be 
confounded by statin indication9. Thus, in the absence of an RCT, it is advised to analyse observational data with a 
statistical approach that improves balance of baseline comorbidities, and this could be achieved with a propensity 
score weighted approach9.
We aimed to first assess whether statin use was associated with a lower rate of rVTE in a prospective cohort 
study with standardised assessment of rVTE, second to examine if the magnitude of the association between sta-
tin use and rVTE using a traditional multivariate statistical analysis approach was comparable with a propensity 
score (PS) weighted approach, and third to explore whether markers of inflammation (ultrasensitive C-Reactive 
Protein [uCRP], fibrinogen) explained the effect of statins.
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Methods
We based our study report on the guidelines provided in the Strengthening the Reporting of Observational stud-
ies in Epidemiology (STROBE) statement10.
Study design, setting, and participants. This study was conducted between September 2nd, 2009 and 
December 6th, 2013. It was part of the Swiss Cohort of Elderly Patients with VTE (SWITCO65+) prospective 
multicentre cohort study, which assessed long-term medical outcomes in elderly patients with acute VTE. 
The study population was recruited from all five university (Basel, Bern, Geneva, Lausanne and Zurich) and 
four high-volume non-university hospitals (cantonal hospitals of Baden, Frauenfeld, Luzern and St. Gallen) in 
Switzerland. The Ethics Committee at each of the nine participating centres approved the study. All research in 
this observational study was performed in accordance with relevant ethics and research guidelines/regulations. 
Informed consent to participate in the SWITCO65+ study was obtained for all enrolled adults. Participants 
aged 65 years or older, with an acute, objectively confirmed symptomatic deep vein thrombosis (DVT) or symp-
tomatic pulmonary embolism (PE), were prospectively recruited in the inpatient and outpatient settings of all 
study sites, and followed-up until December 6th, 2013 (participants were censored earlier in case of death or 
rVTE)11. Symptomatic PE was defined as a positive spiral computed tomography or pulmonary angiography, a 
high probability ventilation-perfusion scan, or proximal DVT confirmed by compression ultrasonography or 
contrast venography, in participants with acute chest pain, new or worsening dyspnoea, haemoptysis, or syncope. 
Those with catheter-related thrombosis, insufficient German-speaking or French-speaking ability, no follow-up 
possibility (e.g. terminal illness), an inability to provide informed consent (e.g. severe dementia), or previous 
enrolment in the cohort, were excluded. The SWITCO65+ study was funded by grants from the Swiss National 
Science Foundation (grants 33CSCO-122659/139470).
Definition of exposures, outcomes, and potential confounders. The main exposure was statin use 
at study entry (statin user vs. non-user). The main outcome was the time to the first recurrence of a symptomatic, 
objectively confirmed VTE (rVTE) during the follow-up period, defined as PE or DVT (proximal and/or distal) 
based on previously published criteria11–13. Follow-up started directly after diagnosis of index VTE. The first 
follow-up took place after three months. During follow-up, study nurses interviewed participants (or respectively 
general practitioners in case of death, or relatives in case of no information [if participant died at home]) about 
the date and type of clinical events (rVTE; death). These interviews were implemented as one telephone call and 
two surveillance face-to-face evaluations during the first year of study participation. Following this, semi-annual 
contact was initiated which alternated between face-to-face evaluations (clinic visits or home visits in house-
bound participants), telephone calls, and periodic review of the participant’s hospital chart. If a clinical event did 
occur, the participant’s medical chart was reviewed, and interviews were held with the participant’s primary care 
physicians and family members.
In addition, information about the following variables that were relevant for the statistical analyses was col-
lected: age (analysed as a continuous variable), smoking history (never, past, current), polypharmacy (<5 drugs 
vs. ≥5 drugs), prior VTE (i.e. a VTE that occurred before the index VTE), transient provoked VTE (surgery 
during the last 3 months, immobilisation during the last 3 months, oestrogen therapy during the last 3 months), 
cardiovascular disease (coronary heart disease, peripheral artery disease, cerebrovascular disease [stroke, TIA]), 
arterial hypertension, diabetes mellitus, body-mass index (BMI) ≥ 25 [yes vs. no], fibrinogen and uCRP (uCRP 
was measured at University Hospital Zurich in serum aliquots using a latex-enhanced immunoturbidimetric 
assay on a cobas c502 autoanalyser [Roche Diagnostics, Mannheim, Germany] with assay characteristics as 
reported by the manufacturer). A committee of three blinded clinical experts adjudicated all outcomes, and final 
classifications were made based on the full consensus of this committee11.
Statistical analyses. We compared baseline characteristics among statin users and non-users with the 
chi-squared test and the non-parametric Wilcoxon rank-sum test as appropriate. rVTE rates were displayed for 
statin users and non-users, as well as stratified into periods with and without anticoagulation. We examined the 
overall association between statin use and the time to a first rVTE using competing risk regression, accounting 
for non-PE-related death as a competing event. The method yields subhazard ratios (SHR) with corresponding 
95%CIs and p-values for the failure event of primary interest. In the traditional statistical analysis approach, we 
adjusted for established risk factors for VTE: age, sex, symptomatic PE, prior VTE, transient provoked VTE, car-
diovascular disease (i.e. coronary heart, peripheral arterial or cerebrovascular [stroke, TIA] disease), active can-
cer, and periods of anticoagulation as a time-varying covariate. In a sensitivity analysis, we additionally adjusted 
for Aspirin, other antiplatelet therapy, hypercholesterolaemia and diabetes after observing that these character-
istics were not evenly distributed among statin users and non-users. In another sensitivity analysis, we stratified 
the results into periods with and without anticoagulation. Moreover, since the study population included both 
provoked and unprovoked index VTE, we also performed subgroup analysis to examine whether the association 
between statin use and rVTE rates was similar between these two groups. Furthermore, we assessed fibrinogen 
and uCRP as potential inflammatory mediators, additionally correcting models for their log-transformed values. 
Beforehand, we performed multiple imputation for missing values of fibrinogen and uCRP.
In the PS weighted analysis approach, we calculated the propensity to receive a statin in a logistic model with 
statin use as dependent and all the variables that were used for adjustment in the main analysis as independent 
variables. The advantage of the PS approach was the ability to not only better balance the two groups (statin users 
and non-users) in terms of baseline characteristics, but to also account for more potential confounders if rVTE 
events were few. Therefore, in the PS approach we additionally adjusted for hypertension, polypharmacy, smoking 
status, and BMI. Missing values for BMI and smoking status were assumed to be normal (i.e. BMI as <25 [n = 4], 
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smoking status as never [n = 3]). For completion, we compared the results from the PS approach with a sensitivity 
analysis from the traditional statistical approach, which adjusted for all the same variables as in the PS analysis.
We trimmed the PS values using the 2.5th percentile of the PS in the statin users as the lower cut-off and the 
97.5th percentile of the PS in the non-users as the upper cut-off. Observations in both groups that had PS val-
ues beyond these two cut-offs were dropped14. We then calculated the inverse probability of treatment weights 
(IPTW) for the remaining participants. The competing risk model was weighted according to the IPTW and 
additionally adjusted for periods of anticoagulation as a time-varying covariate. Again, we stratified the results 
into periods with and without anticoagulation in sensitivity analyses, and also assessed fibrinogen and uCRP as 
potential inflammatory mediators, additionally correcting models for their log-transformed values. We used Stata 
15 for all analyses (Stata Corporation, College Station, Texas).
essentials. 
•	 Statin users have lower rates of recurrent venous thromboembolism (rVTE), but the magnitude of this asso-
ciation is uncertain and could be influenced by concurrent anticoagulation.
•	 While statin therapy was not associated with reduced risk of rVTE during periods of anticoagulation, we 
observed a 50% reduced risk of rVTE with statin therapy during periods without anticoagulation.
•	 Using a propensity score weighted approach, statins were associated with an 80% reduced risk of rVTE during 
periods without anticoagulation.
Results
participants. Between September 2009 and March 2012, 1,003 participants with VTE were enrolled and 
followed until December 201311. For this analysis, we excluded 11 participants with fibrate or ezetimibe treat-
ment (Fig. 1), because these drugs are possibly associated with a higher risk of VTE15,16. We further excluded four 
participants who withdrew informed consent within one day, and eight participants who denied use of their data.
The 980 included participants had a mean age of 75.0 years, 52.7% were men, 99.8% were Caucasian. The 
majority of participants had comorbidities, such as active cancer, chronic lung disease, or heart failure (Table 1). 
Overall, 69.3% of participants had PE at baseline, with or without DVT. Most participants (81.2%) were treated in 
hospital, and low-molecular-weight heparin was administered to 48.6% of participants as initial antithrombotic 
treatment.
241 (24.3%) participants reported statin use compared to 739 non-users. Among the statin users, 103 took 
atorvastatin, 73 simvastatin, 49 pravastatin, 12 rosuvastatin, and 4 fluvastatin. Statin users and non-users had a 
similar age and sex distribution, but statin users were more overweight (BMI ≥ 25 kg/m2: 72% vs. 62%) and were 
generally in a worse medical condition suffering from more comorbidities, with a higher prevalence of diabetes 
mellitus (25% vs. 12%), arterial hypertension (79% vs. 59%), chronic or acute heart failure (19% vs. 9%), coronary 
heart disease (42% vs. 9%), peripheral arterial disease (12% vs. 5%), cerebrovascular disease (21 vs. 5%), past 
major bleeds (15 vs. 9%), and polypharmacy (80 vs. 41%).
Statins and rVte. After a mean follow-up of 27.5 months (median 29.6 months), 21 of the 241 statin users 
(8.7%) experienced a rVTE compared to 99 of the 739 non-users (13.4%). rVTE incidence rates (IR) were 3.8 per 
100 patient-years (95%CI 2.5 to 5.9) among statin users vs. 6.3 per 100 patient-years (95%CI 5.2 to 7.7, p = 0.036) 
among non-users. During periods with anticoagulation, rVTE IR were 2.5 per 100 patient-years (95%CI 1.3 to 
4.8) among statin users vs. 2.3 per 100 patient-years (95%CI 1.5 to 3.5) among non-users. During periods with-
out anticoagulation, rVTE IR were 6.4 per 100 patient-years (95%CI 3.6 to 11.3) among statin users vs. 12.6 per 
100 patient-years (95%CI 10.1 to 15.8) among non-users. Overall, statin users had a 38% reduced risk of rVTE 
Figure 1. Flow-chart enrolment process.
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during follow-up compared to non-users (crude SHR 0.62, 95%CI 0.39 to 1.00, p = 0.05). After adjusting for 
age, sex, symptomatic PE, prior VTE, transient provoked VTE, cardiovascular disease, active cancer, and peri-
ods of anticoagulation as a time-varying covariate, the effect estimate was slightly attenuated (adjusted [a]SHR 
0.72, 95%CI 0.44 to 1.19, p = 0.20; Table 2). In the sensitivity analysis additionally adjusting for Aspirin, other 
Total N
Statin
No statin
p-value
n (%) or median (IQ-range)
N = 241 N = 739
Age [years] 75.0 (70.0; 81.0) 75.0 (69.0; 81.0) 0.63
Females 107 (44%) 351 (47%) 0.40
Smoking status 0.77
  current smoker 18 (7%) 58 (8%)
  past smoker 103 (43%) 295 (40%)
  never smoker 120 (50%) 383 (52%)
Family history of pulmonary embolism/deep vein thrombosis 37 (15%) 125 (17%) 0.57
Known thrombophilia 2 (1%) 11 (1%) 0.44
Diabetes mellitus 61 (25%) 91 (12%) <0.01
Hypercholesterolaemia 206 (85%) 87 (12%) <0.01
Coronary heart disease 101 (42%) 68 (9%) <0.01
Peripheral arterial disease 29 (12%) 40 (5%) <0.01
Cerebrovascular disease (stroke/ transient ischaemic attack) 50 (21%) 40 (5%) <0.01
Cardiovascular disease (coronary/peripheral/
cerebrovascular) 180 (75%) 148 (20%) <0.01
Arterial hypertension <0.01
  no 49 (20%) 301 (41%)
  yes (treated) 189 (78%) 416 (56%)
  yes (untreated) 3 (1%) 22 (3%)
Chronic lung disease 34 (14%) 102 (14%) 0.91
Body-mass index [kg/m2] 27.7 (24.6; 30.8) 26.4 (23.8; 29.7) <0.01
Body-mass index ≥25 174 (72%) 463 (63%) <0.01
Symptomatic pulmonary embolism 186 (77%) 491 (66%) <0.01
Prior venous thromboembolismb 75 (31%) 203 (27%) 0.28
Major surgery during the last 3 months 44 (18%) 102 (14%) 0.09
Current oestrogen therapy during the last 3 months 4 (2%) 28 (4%) 0.11
Immobilisation during the last 3 months 57 (24%) 159 (22%) 0.49
Provoked venous thromboembolism 75 (31%) 219 (30%) 0.66
Active cancer 38 (16%) 138 (19%) 0.31
History of major bleeding 37 (15%) 63 (9%) <0.01
Chronic renal disease 67 (28%) 117 (16%) <0.01
Polypharmacy 193 (80%) 304 (41%) <0.01
Anticoagulation prior to venous thromboembolism 19 (8%) 32 (4%) 0.03
Initial parenteral anticoagulation 232 (96%) 714 (97%) 0.80
Type of initial parenteral anticoagulation 0.02
  Low molecular weight heparin 94 (39%) 366 (50%)
  Unfractionated heparin 97 (40%) 233 (32%)
  Fondaparinux 40 (17%) 115 (16%)
  Danaparoid 1 (0%) 0 (0%)
  None 9 (4%) 25 (3%)
Initial vitamin K antagonist therapy 211 (88%) 640 (87%) 0.705
Concomitant antiplatelet therapy 149 (62%) 166 (22%) <0.001
Aspirin 127 (53%) 154 (21%) <0.001
Duration of initial anticoagulation [months] 11.1 (5.2; 28.7) 7.1 (3.7; 23.7) 0.012
Fibrinogen at the time of venous thromboembolism [g/L] 4.8 (3.7; 5.8) 4.5 (3.6; 5.6) 0.102
Ultrasensitive C-Reactive Protein at the time of venous 
thromboembolism [mg/L] 22.2 (6.1; 63.6) 23.6 (8.5; 62.1) 0.260
Table 1. Baseline characteristics of statin users and non-usersa. aMissing: 3 (0%) for smoking status, 8 (1%) for 
family history of venous thromboembolism, 18 (2%) for systolic blood pressure, 4 (0%) for body-mass index, 
1 (0%) for oestrogen therapy, 1 (0%) for history of major bleeding, 125 (13%) for fibrinogen, 124 (13%) for 
ultrasensitive C-Reactive Protein. bVenous thromboembolism prior to the index venous thromboembolism.
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antiplatelet therapy, hypercholesterolaemia and diabetes, statins were more strongly associated with rVTE (aSHR 
0.56, 95%CI 0.32 to 0.99, p = 0.05). When only time-periods with anticoagulation were considered, there was 
no association between statin use and rVTE (aSHR 1.34, 95%CI 0.54 to 3.35, p = 0.53). In contrast, when only 
time-periods without anticoagulation were considered, statin use was more strongly associated with rVTE (aSHR 
0.50, 95%CI 0.27 to 0.92, p = 0.03). Upon subgroup analysis, the incidence rates of rVTE were slightly lower in 
patients with a provoked index VTE (IR 4.6 per 100 patient-years, 95%CI 3.2 to 6.6) compared to unprovoked 
index VTE patients (IR 6.1 per 100 patient-years, 95%CI 5.0 to 7.5). Nevertheless, reduction in rVTE risk with 
statin use compared to non-use was still similar among the two subgroups (provoked index VTE - aSHR 0.71, 
95%CI 0.24 to 2.15, p = 0.55; unprovoked VTE - aSHR 0.68, 95%CI 0.39 to 1.20, p = 0.19); confirming that there 
was no observable subgroup effect (p for interaction 0.93). Neither fibrinogen nor uCRP had an impact on the 
results (aSHR including fibrinogen 0.75, 95%CI 0.45 to 1.23, p = 0.25; aSHR including uCRP 0.72, 95%CI 0.43 to 
1.19, p = 0.20; Table 2).
In the PS weighted analysis (based on 792 participants with 99 rVTEs), we observed a more pronounced 
rVTE risk reduction of 58% among statin users compared to non-users (aSHR 0.42, 95%CI 0.21 to 0.81, p = 0.01). 
Again, the association became stronger during periods without anticoagulation (aSHR 0.20, 95%CI 0.08 to 
0.49, p < 0.001), whereas it was not observed during periods of anticoagulation (aSHR 1.17, 95%CI 0.47 to 2.90, 
p = 0.74). Further, neither fibrinogen nor uCRP had an impact on the results (aSHR including fibrinogen 0.43, 
95%CI 0.22 to 0.84, p = 0.01; aSHR including uCRP 0.41, 95%CI 0.21 to 0.80, p = 0.01; Table 2). In a sensitivity 
analysis using the traditional statistical analysis approach, but adjusting for all variables that were used in the PS 
analysis, the association between statin use and rVTE was slightly stronger compared to the original multivariable 
approach (aSHR 0.60, 95%CI 0.36 to 1.01, p = 0.06 vs. aSHR 0.72, 95%CI 0.44 to 1.19, p = 0.20).
Discussion
In this population-based prospective cohort study, we found a lower rate of rVTE among statin users compared to 
non-users, but this beneficial association was only apparent during periods without anticoagulation, and stronger 
in the PS weighted approach than in the traditional statistical analysis approach. Furthermore, the potentially 
beneficial effect of statins was not explained by markers of inflammation such as fibrinogen or uCRP.
Number of events/
Number of patients Analysis
Crude subhazard 
ratio (95%-CI) p-value
Adjusted subhazard 
ratio (95%-CI) p-value
Traditional statistical analysis approach
120/980 Overall 0.62 (0.39 to 1.00) 0.049 0.72 (0.44 to 1.19)a 0.197
31/972 Periods with AC 1.16 (0.54 to 2.49) 0.707 1.34 (0.54 to 3.35)a 0.525
89/595 Periods without AC 0.52 (0.28 to 0.95) 0.034 0.50 (0.27 to 0.92)a 0.027
Sensitivity analysis including same variables 
as the propensity score approach 0.60 (0.36 to 1.01)
b 0.056
Including markers of inflammation
120/980 Fibrinogen 0.75 (0.45 to 1.23)c 0.250
120/980 ultrasensitive CRP 0.72 (0.43 to 1.19)c 0.197
Propensity score weighted approachd
99/792 Overall 0.60 (0.34 to 1.03) 0.064 0.42 (0.21 to 0.81)e 0.010
28/788 Periods with AC 1.34 (0.60 to 3.01) 0.481 1.17 (0.47 to 2.90)e 0.740
71/477 Periods without AC 0.38 (0.18 to 0.84) 0.016 0.20 (0.08 to 0.49)e <0.001
Including markers of inflammation
99/792 Fibrinogen 0.43 (0.22 to 0.84)c 0.014
99/792 ultrasensitive CRP 0.41 (0.21 to 0.80)c 0.009
Table 2. Statin therapy and rVTE. AC = anticoagulation, CRP = C-Reactive Protein. aAdjusted for age, gender, 
symptomatic pulmonary embolism, prior venous thromboembolism, provoked venous thromboembolism, 
cardiovascular disease (i.e. coronary heart, peripheral arterial or cerebrovascular [stroke, transient ischaemic 
attack] disease), active cancer, and periods of anticoagulation as a time-varying covariate. bSensitivity 
analysis: further adjustment for the same variables as used in the propensity score approach. Adjusted to 
include age, gender, symptomatic pulmonary embolism, prior venous thromboembolism, provoked venous 
thromboembolism, cardiovascular disease (i.e. coronary heart, peripheral arterial or cerebrovascular [stroke, 
transient ischaemic attack] disease), active cancer, periods of anticoagulation as a time-varying covariate, 
and additionally hypertension, polypharmacy, smoking (never/past/current), body-mass index (≥25). cTwo 
separate additional adjustment variables: log-Fibrinogen and log-ultrasensitive C-Reactive Protein (as potential 
explanatory variables of the association between statins and rVTE). Multiple imputation for missing values of 
fibrinogen and ultrasensitive C-Reactive Protein was performed. dVariables used to calculate the propensity 
score: age, gender, symptomatic pulmonary embolism, prior venous thromboembolism, provoked venous 
thromboembolism, cardiovascular disease (i.e. coronary heart, peripheral arterial or cerebrovascular [stroke, 
transient ischaemic attack] disease), active cancer, hypertension, polypharmacy, smoking (never/past/current), 
and body-mass index (≥25). eThe adjusted model was weighted according to inverse probability of treatment 
weights (IPTW) and additionally adjusted for periods of anticoagulation as a time-varying covariate.
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Our results from the traditional statistical analysis approach were very similar to a recent meta-analysis of 
eight observational studies5, indicating an almost 30% risk reduction in rVTE with statin therapy. However, our 
results suggest that statins may only reduce the risk for rVTE in the absence of anticoagulation. Therefore, they 
might be a second best option to prevent rVTE when anticoagulation is contraindicated. Moreover, under the 
PS weighted approach, the risk reduction became even more substantial (i.e. 80% during periods without anti-
coagulation). There are arguments supporting the hypothesis that the traditional statistical analysis approach 
underestimates the true effect of statins in observational studies: statin users have more comorbidities and are 
sicker than non-users6,7, which is also observed in our own study population’s baseline characteristics (Table 1), 
and multimorbid persons have a higher risk of VTE8. Thus, the potentially beneficial effect of statins could be 
partly concealed by comparing multimorbid statin users with healthier non-users in observational studies using a 
traditional multivariable statistical analysis approach. In contrast, in the PS weighted approach, participants with 
a PS value below the 2.5th percentile and above the 97.5th percentile were discarded, as at these extremes of range 
there was no comparable participant in the other group with similar comorbidities/risk profile, thus making the 
two groups (statin users vs. non-users) as similar as possible14.
Our study has several limitations. First, the study population was recruited consecutively from most 
large-volume hospitals in Switzerland. As a result, it is uncertain if the results also apply to patients with poten-
tially less severe (r)VTE who were treated in smaller hospitals or by general practitioners. Second, almost all 
study participants were white, so our results are only generalisable to a Caucasian population. Third, we tested 
if the potential beneficial effect of statins was explained by a reduction in inflammation – we observed no such 
association. Yet, we only considered fibrinogen and uCRP. Both markers have been suggested by previous studies 
to be affected by statin therapy17,18. It is possible that statins reduce the risk of (r)VTE via other inflammatory 
markers for which we had no information available or via direct impact on endothelial function17,19. In fact, 
newly published data suggests that the protective effect of statins in decreasing rVTE rates may not be down to a 
reduction in inflammation, but rather due to a reduction in coagulation factors20. Fourth, our study did not have 
sufficient power to analyse different statin agents separately, and it is possible that the risk reduction seen in (r)
VTE is statin-specific and therefore, cannot be attributed to a class-effect21,22. Fifth, all participants were 65 years 
or older. Therefore, it is uncertain whether our results also apply to a younger population. Sixth, whether or not a 
participant used statins was only assessed at baseline. Therefore, our exposure assessment (i.e. statin use) might 
be inaccurate in cases where participants started or stopped statin therapy during follow-up. However, as this 
inaccuracy is not related to the outcome of interest (rVTE), results may at worst be biased towards the null (i.e. 
underestimate the association between statin use and rVTE).
Our study has several strengths. First, it highlights that statistical analysis approaches accounting for con-
founding by indication (i.e. the PS weighted approach) can produce different results from traditional multivaria-
ble analyses of observational data. Analysing observational data with both a traditional multivariable analysis and 
a PS weighted analysis, comparing the findings and attempting to explain differences, can result in new insights. 
Furthermore, it makes optimal use of already existing data. Second, our study included elderly patients with VTE 
(mean age 75 years), a population that is often underrepresented or excluded from clinical trials. Third, the cohort 
had a small dropout rate of 4.8% during follow-up11, and the data collection was near complete with less than 5% 
missing values. Fourth, rVTE was adjudicated by a blinded expert committee using clearly defined previously 
published objective criteria11–13, reducing the risk of detection bias. Finally, both inpatients and outpatients with 
an index VTE were included in a nationwide multicentre setting.
conclusion
Statin use was associated with a more pronounced risk reduction for rVTE than previously estimated, but only 
without concurrent anticoagulation. An RCT would be needed to substantiate the potential benefits of statins for 
prevention of rVTE during periods when anticoagulation is not indicated or feasible.
Data Availability
All necessary data that support the findings of this study are included within this published article. Any further 
supplemental data is available from the authors upon request.
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